Marriott (MAR) CEO Arne Sorenson has announced that he will not be taking a salary for the rest of the year, responding to the fallout from the coronavirus. ...
Airline stocks like American Airlines (NASDAQ:AAL) have been wiped out in this selloff. Since Feb. 12, AAL stock has lost 62% of its value.Source: GagliardiPhotography / Shutterstock.com American is not alone. Among the four major U.S. airlines, Southwest Airlines (NYSE:LUV) is the "winner" over the stretch, with a 40% decline. Delta Air Lines (NYSE:DAL) has matched AAL's drop. United Airlines (NASDAQ:UAL) has lost three-fourths of its value.After those declines, some investors might believe the worst is priced in for AAL stock, and the sector. They should rethink that opinion. It absolutely can get worse. In fact, for American, another bankruptcy remains a potential outcome -- in which case, the downside is another 100%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOn its own, it will at least take American many months, and likely several years, to convince the market its financial position is sound. In the meantime, AAL stock is...
The coronavirus pandemic has forced economic shutdowns around the world, as nations and governments try to cope with the ill and prevent or slow the further spread of the disease. Stock markets have crashed in recent weeks; the Dow Jones is down 32% from its most recent peak, and the S&P 500 has lost 29%. With the advent of a true bear market cycle, economists are growing more certain in their warnings of a recession this year.But despite the near-certainty that an epidemic-related recession is on the way (or already here), there is considerable doubt that it will be long-lasting in its effects. Economic conditions were reasonably strong before the coronavirus hit, and both the January and February jobs reports showed better than expected gains in employment and increases in wages. So, it may be no surprise that investment bank Morgan Stanley sees current conditions as an opportunity for traders.Expanding on...
BNY Mellon Chief Strategist Alicia Levine joins Yahoo Finance’s Alexis Christoforous, Brian Sozzi, Brian Cheung and Jared Blikre to discuss the latest market action. ...
Remember when investors were focused on whether the 5G revolution would live up to its reality? Yeah, so do I. And Qualcomm (NASDAQ:QCOM) is surely wishing the only question investors would be asking is if Qualcomm stock was overvalued at $88 per share.Source: Katherine Welles / Shutterstock.com In early March, Piper Sandler analyst Harsh Kumar initiated his coverage on Qualcomm stock. At the time (just two weeks ago), he gave the stock a "neutral" rating with a price target of around $80, but was bearish on the stock.His expectation was that Qualcomm's stock price seemed to have properly factored in the growth it would get from 5G smartphone sales.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI still believe that 5G is going to set up Qualcomm stock for some healthy gains. However, the stock probably has further to fall before that happens. What a Difference One Month MakesOne month...
History suggests that General Electric (NYSE:GE) stock is a buy here. As I write this, General Electric stock trades at $6.60. The stock has bottomed at those levels before.Source: testing / Shutterstock.com During the financial crisis, in March 2009, GE stock touched a closing low of $6.40. It would clear $10 before the month was out, and finish 2009 above $14. On Dec. 12, 2018, during the market's last correction, GE closed at $6.45. By February, the stock was back above $10.After a sell-off of nearly 50% in little over a month, General Electric stock is re-testing those past lows. And no doubt some investors believe history will repeat.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI'm one of those investors -- but not because I'm a bull on GE. Rather, as I've argued consistently during this sell-off, I believe U.S. stocks as a whole will bounce back. That rising...
Sorrento Therapeutics Inc (NASDAQ: SRNE), which is being touted as a takeover target, announced Friday it's working on potential preventative treatment for SARS-CoV-2, the virus that causes COVID-19.The San Diego, California-based company, which is engaged in the development of new therapies for cancer, said it has produced a pre-clinical batch of STI-4398 aka "COVIDTRAP' protein and would immediately start testing its neutralizing and blocking activity in preventing the virus from infecting angiotensin-converting enzyme 2, or ACE2-expressing cells.STI-4398, according to Sorrento, is a proprietary ACE2-Fc fusion protein that binds to the S1 domain of the spike protein. This could block the spike protein of the virus and prevent it from binding to the ACE2 receptors present on the target respiratory epithelial cells. Unable to penetrate the target cells, the virus loses its ability to replicate and spread.This approach is likely to come in handy to generate passive immunity and shield at-risk populations...